Jiangsu Aidea Pharmaceutical Group Co., Ltd. (SHA:688488)

China · Delayed Price · Currency is CNY

13.98

+0.79 (5.99%)

Aug 4, 2026, 3:00 PM CST

SHA:688488 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	699.33	719.17	417.8	411.36	244.22	255.71
Revenue Growth	33.77%	72.13%	1.57%	68.44%	-4.49%	-11.54%
Gross Profit	460.79	463.34	193.28	166.36	72.04	74.38
Operating Income	29.53	34.76	-142.11	-106.03	-171.64	-62.34
Net Income	-27.51	-19.53	-141.2	-76.07	-124.09	-29.99
Earnings Per Share	-0.07	-0.05	-0.34	-0.18	-0.30	-0.07
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
Biomedical Raw Materials	57.84
Pharmaceutical Manufacturing	660.33
Total	718.18

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	534.06	451.35	441.52	441.1	486.54	606.02
Total Debt	719.92	559.15	488.03	412.3	208.77	5.59
Net Cash (Debt)	-185.85	-107.8	-46.5	28.8	277.78	600.43
Net Cash Growth	-	-	-	-89.63%	-53.74%	-23.12%
Net Cash Per Share	-0.44	-0.26	-0.11	0.07	0.67	1.40

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-21.23	17.63	-37.5	-166.22	-92.55	-12.37
Capital Expenditures	-45.23	-47.93	-44.56	-71.2	-140.3	-94.78
Free Cash Flow	-66.46	-30.3	-82.06	-237.43	-232.85	-107.15
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	65.89%	64.43%	46.26%	40.44%	29.50%	29.09%
Operating Margin	4.22%	4.83%	-34.01%	-25.78%	-70.28%	-24.38%
Pretax Margin	1.28%	3.43%	-39.73%	-22.39%	-58.30%	-16.53%
Profit Margin	-3.93%	-2.72%	-33.80%	-18.49%	-50.81%	-11.73%
FCF Margin	-9.50%	-4.21%	-19.64%	-57.72%	-95.34%	-41.90%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 4, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Forward PE	-	145.16	-	-	-	-
PS Ratio	8.41	9.56	7.92	12.80	18.13	25.57